Currently, about 70 teams are working on a COVID-19 vaccine. These include pharmaceutical concerns, smaller biotechnology companies, academia and non-profit organizations. As impressive as the race is, it’s worth looking at what’s happening in its shadow: the challenge of developing a distribution model. And the venture is unprecedented, as it will involve millions of patients around the world.